人子宫内膜癌细胞USPC-ARK-1

细胞名称

人子宫内膜癌细胞USPC-ARK-1

货物编码

BFN60808667

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研     2类

培养体系

DMEM高糖+10%FBS+1%三抗

培养温度

37℃

二氧化碳浓度

5%

简介

人子宫内膜癌细胞USPC-ARK-1取自62岁女性供体，贴壁培养。

注释

Endometrial serous adenocarcinoma

基因突变

PIK3CA p.Glu542Lys (c.1624G>A) (PubMed=23891627; PubMed=26325104).

HLA信息

/

STR信息

/

参考文献

PubMed=19920829; DOI=10.1038/sj.bjc.6605448

El-Sahwi K., Bellone S., Cocco E., Cargnelutti M., Casagrande F., Bellone M., Abu-Khalaf M., Buza N., Tavassoli F.A., Hui P., Silasi D.-A., Azodi M., Schwartz P.E., Rutherford T.J., Pecorelli S., Santin A.D.

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.

Br. J. Cancer 102:134-143(2010)

PubMed=21246534; DOI=10.1002/cncr.25891

Varughese J., Cocco E., Bellone S., de Leon M., Bellone M., Todeschini P., Schwartz P.E., Rutherford T.J., Pecorelli S., Santin A.D.

Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.

Cancer 117:3163-3172(2011)

PubMed=23891627; DOI=10.1016/j.ajog.2013.07.020

English D.P., Bellone S., Cocco E., Bortolomai I., Pecorelli S., Lopez S., Silasi D.-A., Schwartz P.E., Rutherford T., Santin A.D.

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).

Am. J. Obstet. Gynecol. 209:465.e1-465.e9(2013)

PubMed=26325104; DOI=10.1038/bjc.2015.306

Black J.D., Lopez S., Cocco E., Bellone S., Altwerger G., Schwab C.L., English D.P., Bonazzoli E., Predolini F., Ferrari F., Ratner E., Silasi D.-A., Azodi M., Schwartz P.E., Santin A.D.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.

Br. J. Cancer 113:1020-1026(2015)

PubMed=26625219; DOI=10.1038/bjc.2015.388

Black J.D., Lopez S., Cocco E., Bellone S., Altwerger G., Schwab C.L., English D.P., Bonazzoli E., Predolini F., Ferrari F., Ratner E., Silasi D.-A., Azodi M., Schwartz P.E., Santin A.D.

Erratum to: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.

Br. J. Cancer 113:1641-1641(2015)